Modelling Spillover Effects on Informal Carers: The Carer QALY Trap

David J. Mott (), Hannah Schirrmacher (), Hareth Al-Janabi (), Sophie Guest (), Becky Pennington (), Nicolas Scheuer (), Koonal K. Shah () and Chris Skedgel ()
Additional contact information
David J. Mott: Office of Health Economics
Hannah Schirrmacher: Office of Health Economics
Hareth Al-Janabi: University of Birmingham
Sophie Guest: Roche Products Ltd
Becky Pennington: University of Sheffield
Nicolas Scheuer: Roche Products Ltd
Koonal K. Shah: National Institute for Health and Care Excellence
Chris Skedgel: Office of Health Economics

PharmacoEconomics, 2023, vol. 41, issue 12, No 2, 1557-1561

Abstract: Abstract The provision of informal (unpaid) care can impose significant ‘spillover effects’ on carers, and accounting for these effects is consistent with the efficiency and equity objectives of health technology assessment (HTA). Inclusion of these effects in health economic models, particularly carer health-related quality of life (QOL), can have a substantial impact on net quality-adjusted life year (QALY) gains and the relative cost effectiveness of new technologies. Typically, consideration of spillover effects improves the value of a technology, but in some circumstances, consideration of spillover effects can lead to situations whereby life-extending treatments for patients may be considered cost ineffective due to their impact on carer QOL. In this piece we revisit the classic ‘QALY trap’ and introduce an analogous ‘carer QALY trap’ which may have practical implications for economic evaluations where the inclusion of carer QOL reduces incremental QALY gains. Such results may align with a strict QALY-maximisation rule, however we consider the extent to which this principle may be at odds with the preferences of carers themselves (and possibly society more broadly), potentially leading decision makers into the carer QALY trap as a result. We subsequently reflect on potential solutions, highlighting the important (albeit limited) role that deliberation has to play in HTA.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.1007/s40273-023-01316-0 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:41:y:2023:i:12:d:10.1007_s40273-023-01316-0

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-023-01316-0

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().